# Clinical Trials Data KIT - Document 57

# Tracking Technologies for the Analysis of Mobility in Alzheimer's Disease

## Clinical Trial: https://clinicaltrials.gov/study/NCT00743418

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Patients with MCI, Alzheimer's disease, or mixed type dementia; OR\n\* Healthy control subjects who meet the following criteria:\n\n \* Mini Mental State (MMSE) of at least 21\n \* Age 60 years or older\n \* Patients with history of stroke which is not followed by cognitive decline may be included\n \* Fluent language skills\n\nExclusion Criteria:\n\n\* Other dementias (e.g. vascular, frontotemporal, metabolic etc);\n\* Other major psychiatric disorders (e.g. major depression, schizophrenia);\n\* Substance abuse;\n\* MMSE 20 or less;\n\* Severe motor disturbances;\n\* Sensory deficits potentially affecting mobility; OR\n\* Severe physical disorders (e.g. cancer, major operation)",  
 "healthyVolunteers": true,  
 "sex": "ALL",  
 "minimumAge": "60 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided clinical trial information, whether a patient with a KIT gene mutation would be eligible depends not on the mutation itself, as it is not mentioned in the inclusion or exclusion criteria, but on the other criteria listed. The trial focuses on patients with MCI (Mild Cognitive Impairment), Alzheimer's disease, or related conditions, as well as healthy control subjects over the age of 60. The KIT gene mutation is not a factor in the eligibility criteria.  
  
To assess eligibility:  
  
1. A patient with a KIT gene mutation directly isn't excluded unless they have:  
 - A type of dementia other than MCI or Alzheimer's (like vascular dementia).  
 - A major psychiatric disorder.  
 - Substance abuse issues.  
 - An MMSE score of 20 or less.  
 - Severe motor disturbances or sensory deficits affecting mobility.  
 - Severe physical disorders.  
  
2. The patient must meet the age requirement (60 years or older) and have the appropriate cognitive status (MMSE score of at least 21 for control subjects).  
  
If the patient's condition aligns with these criteria and they do not have any of the exclusion conditions listed, they would likely be eligible for the clinical trial, regardless of their KIT gene mutation status.